RSV Vaccination in an Older Adult with a Remote, Infection-Triggered Guillain-Barré History
An older man with COPD and a remote, infection-triggered episode of Guillain-Barré syndrome is offered RSV vaccination. A new, small post-marketing safety signal for the vaccine sits uneasily against a history that most guidance says shouldn’t count against him — but nobody is fully certain why the signal exists yet.
D.K., a 74-year-old man, drove a regional delivery route for thirty-one years before COPD — moderate, on tiotropium and an as-needed rescue inhaler — forced him into retirement four years earlier than he'd planned. He still walks his neighbor's dog twice a day and describes himself as "slower than I was, not sick," but two winter bronchitis flares last year both landed him briefly in urgent care, and his pulmonologist has been raising RSV vaccination at each visit since. Six years ago he developed ascending limb weakness ten days after a severe diarrheal illness that was later confirmed as Campylobacter jejuni on stool culture, was hospitalized for eleven days with a clinical and electrodiagnostic picture consistent with Guillain-Barré syndrome, and recovered with only mild residual numbness in his toes — no wheelchair, no ventilator, no recurrence since.
Campylobacter is one of the best-established infectious triggers of GBS, well described independent of anything related to vaccination, which is part of why his own history isn't the pattern the standing vaccine precaution was written around: a GBS episode within six weeks of a prior dose of influenza or tetanus-toxoid-containing vaccine is what that precaution names, and his episode has no vaccine in it at all. What complicates a case that would otherwise look straightforward is that the signal on the other side is no longer merely a signal. In January 2025 the FDA required both RSV vaccines to carry a Guillain-Barré warning in the Warnings and Precautions section of their prescribing information, on the strength of a post-marketing self-controlled case series in Medicare beneficiaries aged 65 and older that estimated roughly nine excess GBS cases per million doses of the bivalent RSVpreF product and seven per million of the adjuvanted GSK product within 42 days — with the agency stating plainly that the evidence suggests increased risk but is insufficient to establish causation. A subsequent national analysis in England put the figure higher, a relative incidence of 3.34 and an attributable risk near 23 cases per million doses. These are still small absolute numbers, and both CDC and FDA have held that benefit-risk favors vaccination in the recommended groups. But the drug he is being offered now carries a labeled warning for the exact condition he has already had once. Nobody yet knows whether that warning reflects something specific to the vaccine antigen or a broader susceptibility that any strong immune stimulus could trigger in a nervous system that has already demyelinated once — which is the question his own case sits on: a real prior episode, a real but different trigger, and a labeled risk whose mechanism is unresolved.
Pulmonology clinic, RSV vaccination discussion
I want to be precise about what we don't know, not just what we do. His GBS followed an infection, not a vaccine, and that matters — but I'd note this has moved past surveillance chatter: the FDA put a GBS warning in the Warnings and Precautions section of both labels in January 2025. What that warning doesn't tell us is whether the excess risk is specific to something in the vaccine antigen or reflects a broader susceptibility in anyone whose nervous system has already mounted one demyelinating immune response, regardless of what set it off the first time. A second episode, even if rare, would be a real and possibly worse event in a 74-year-old. Until that mechanism question has a clearer answer, I would lean toward deferring RSV vaccination for him specifically, not the general population.
You're right that the mechanism question is genuinely open — I don't think anyone can close it today. But I'd weigh what we can quantify against what we can't. His COPD and age put him concretely in the group RSV hospitalizes and kills at real, well-documented rates — and at 74 with chronic lung disease he is squarely inside the 60-to-74-with-risk-factors group CDC still recommends, not at its margin. RENOIR, the trial supporting the bivalent RSVpreF product we'd actually be giving him, showed meaningful reductions in RSV-associated lower respiratory tract disease in his age and comorbidity bracket; AReSVi-006 did the same for the GSK adjuvanted product, which is a different vaccine and not interchangeable evidence. Against that, the FDA's own Medicare estimate is roughly nine excess GBS cases per million doses within 42 days, and even England's higher figure of about 23 per million is a number I can put next to his two urgent-care winters. Neither ACIP nor either label lists a remote, non-vaccine-triggered GBS history as a contraindication or precaution. I'd recommend proceeding.
Deferring "until the mechanism is clearer" sounds cautious, but there's no fixed date that resolves — surveillance data accumulates gradually, and a blanket deferral for anyone with any GBS history, regardless of trigger, isn't what the data we actually have supports.
I don't think this needs to resolve into either "defer" or "proceed as if his history is irrelevant." Current understanding leans toward some shared immune-mediated demyelinating pathway regardless of what triggers it, which means his history probably isn't fully reassuring — but none of the studies behind that label change were powered to say anything about prior-GBS patients specifically, because prior GBS is exactly who those cohorts contain least of. That argues for proceeding on an informed basis rather than a default one: tell him plainly what's known and not known, and give him explicit early-warning instructions — any new limb weakness, tingling, or gait change in the six weeks after vaccination should bring him back immediately, not wait for a scheduled follow-up.
Agreed: proceed with bivalent RSVpreF vaccination today, with explicit, written early-symptom counseling and a direct instruction to call rather than wait for his next scheduled visit if anything neurologic changes in the following six weeks. D.K., once the actual numbers and the genuine uncertainty were both laid out plainly, said he'd rather take a small, honestly-described risk than another winter admission — his words, not the team's framing.
Not agreed: what the right default recommendation should be for a patient like him going forward. The neurologist's caution was heard and is on record, not overruled by consensus — the team proceeded on this patient's own stated preference once informed, not because his objection was resolved. Whether a remote, non-vaccine-triggered GBS history should carry any weight at all in this decision remains a genuinely open question the group did not settle.